263 related articles for article (PubMed ID: 1306111)
1. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites.
Butler MA; Lang NP; Young JF; Caporaso NE; Vineis P; Hayes RB; Teitel CH; Massengill JP; Lawsen MF; Kadlubar FF
Pharmacogenetics; 1992 Jun; 2(3):116-27. PubMed ID: 1306111
[TBL] [Abstract][Full Text] [Related]
2. Analysis of within-subject variation of caffeine metabolism when used to determine cytochrome P4501A2 and N-acetyltransferase-2 activities.
McQuilkin SH; Nierenberg DW; Bresnick E
Cancer Epidemiol Biomarkers Prev; 1995 Mar; 4(2):139-46. PubMed ID: 7742721
[TBL] [Abstract][Full Text] [Related]
3. Xanthine oxidase inhibition by allopurinol affects the reliability of urinary caffeine metabolic ratios as markers for N-acetyltransferase 2 and CYP1A2 activities.
Fuchs P; Haefeli WE; Ledermann HR; Wenk M
Eur J Clin Pharmacol; 1999 Jan; 54(11):869-76. PubMed ID: 10027663
[TBL] [Abstract][Full Text] [Related]
4. Comparison of CYP1A2 and NAT2 phenotypes between black and white smokers.
Muscat JE; Pittman B; Kleinman W; Lazarus P; Stellman SD; Richie JP
Biochem Pharmacol; 2008 Oct; 76(7):929-37. PubMed ID: 18703023
[TBL] [Abstract][Full Text] [Related]
5. Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene.
Nakajima M; Yokoi T; Mizutani M; Shin S; Kadlubar FF; Kamataki T
Cancer Epidemiol Biomarkers Prev; 1994; 3(5):413-21. PubMed ID: 7920209
[TBL] [Abstract][Full Text] [Related]
6. Cytochrome P4501A2: enzyme induction and genetic control in determining 4-aminobiphenyl-hemoglobin adduct levels.
Landi MT; Zocchetti C; Bernucci I; Kadlubar FF; Tannenbaum S; Skipper P; Bartsch H; Malaveille C; Shields P; Caporaso NE; Vineis P
Cancer Epidemiol Biomarkers Prev; 1996 Sep; 5(9):693-8. PubMed ID: 8877060
[TBL] [Abstract][Full Text] [Related]
7. Extractionless method for the simultaneous high-performance liquid chromatographic determination of urinary caffeine metabolites for N-acetyltransferase 2, cytochrome P450 1A2 and xanthine oxidase activity assessment.
Nyéki A; Biollaz J; Kesselring UW; Décosterd LA
J Chromatogr B Biomed Sci Appl; 2001 May; 755(1-2):73-84. PubMed ID: 11393735
[TBL] [Abstract][Full Text] [Related]
8. [Determination of caffeine metabolite for the evaluation of N-acetyltransferase, CYP1A2 and xanthine oxidase activities].
Lu JF; Yi T; Cao XM; Zhuo HT; Ling SS
Yao Xue Xue Bao; 1997 Nov; 32(11):813-8. PubMed ID: 11596199
[TBL] [Abstract][Full Text] [Related]
9. NAT2 and CYP1A2 phenotyping with caffeine: head-to-head comparison of AFMU vs. AAMU in the urine metabolite ratios.
Nyéki A; Buclin T; Biollaz J; Decosterd LA
Br J Clin Pharmacol; 2003 Jan; 55(1):62-7. PubMed ID: 12534641
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations.
Fuhr U; Rost KL; Engelhardt R; Sachs M; Liermann D; Belloc C; Beaune P; Janezic S; Grant D; Meyer UA; Staib AH
Pharmacogenetics; 1996 Apr; 6(2):159-76. PubMed ID: 9156694
[TBL] [Abstract][Full Text] [Related]
11. Combined effects of well-done red meat, smoking, and rapid N-acetyltransferase 2 and CYP1A2 phenotypes in increasing colorectal cancer risk.
Le Marchand L; Hankin JH; Wilkens LR; Pierce LM; Franke A; Kolonel LN; Seifried A; Custer LJ; Chang W; Lum-Jones A; Donlon T
Cancer Epidemiol Biomarkers Prev; 2001 Dec; 10(12):1259-66. PubMed ID: 11751443
[TBL] [Abstract][Full Text] [Related]
12. Acetylation phenotype and cytochrome P450IA2 phenotype are unlikely to be associated with peripheral arterial disease.
Ilett KF; Castleden WM; Vandongen YK; Stacey MC; Butler MA; Kadlubar FF
Clin Pharmacol Ther; 1993 Sep; 54(3):317-22. PubMed ID: 8375127
[TBL] [Abstract][Full Text] [Related]
13. Interaction of ibuprofen and probenecid with drug metabolizing enzyme phenotyping procedures using caffeine as the probe drug.
Vrtic F; Haefeli WE; Drewe J; Krähenbühl S; Wenk M
Br J Clin Pharmacol; 2003 Feb; 55(2):191-8. PubMed ID: 12580991
[TBL] [Abstract][Full Text] [Related]
14. Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activity in humans.
Rasmussen BB; Brøsen K
Ther Drug Monit; 1996 Jun; 18(3):254-62. PubMed ID: 8738764
[TBL] [Abstract][Full Text] [Related]
15. Segregation analyses of four urinary caffeine metabolite ratios implicated in the determination of human acetylation phenotypes.
Vincent-Viry M; Pontes ZB; Gueguen R; Galteau MM; Siest G
Genet Epidemiol; 1994; 11(2):115-29. PubMed ID: 8013893
[TBL] [Abstract][Full Text] [Related]
16. Quantitation of three-month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2, N-acetyltransferase-2, and xanthine oxidase activity determined with caffeine phenotyping.
Kashuba AD; Bertino JS; Kearns GL; Leeder JS; James AW; Gotschall R; Nafziger AN
Clin Pharmacol Ther; 1998 May; 63(5):540-51. PubMed ID: 9630827
[TBL] [Abstract][Full Text] [Related]
17. Caffeine metabolic ratios for the in vivo evaluation of CYP1A2, N-acetyltransferase 2, xanthine oxidase and CYP2A6 enzymatic activities.
Hakooz NM
Curr Drug Metab; 2009 May; 10(4):329-38. PubMed ID: 19519341
[TBL] [Abstract][Full Text] [Related]
18. In vivo evaluation of CYP1A2, CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios.
Begas E; Kouvaras E; Tsakalof A; Papakosta S; Asprodini EK
Biomed Chromatogr; 2007 Feb; 21(2):190-200. PubMed ID: 17221922
[TBL] [Abstract][Full Text] [Related]
19. Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increase the risk for colorectal cancer or polyps.
Lang NP; Butler MA; Massengill J; Lawson M; Stotts RC; Hauer-Jensen M; Kadlubar FF
Cancer Epidemiol Biomarkers Prev; 1994 Dec; 3(8):675-82. PubMed ID: 7881341
[TBL] [Abstract][Full Text] [Related]
20. Urinary mutagenicity, CYP1A2 and NAT2 activity in textile industry workers.
Fanlo A; Sinuès B; Mayayo E; Bernal L; Soriano A; Martínez-Jarreta B; Martínez-Ballarín E
J Occup Health; 2004 Nov; 46(6):440-7. PubMed ID: 15613766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]